RTS, S/AS01 vaccine (Mosquirix™): an overview
MB Laurens - Human vaccines & immunotherapeutics, 2020 - Taylor & Francis
Malaria is an illness caused by Plasmodium parasites transmitted to humans by infected
mosquitoes. Of the five species that infect humans, P. falciparum exacts the highest toll in …
mosquitoes. Of the five species that infect humans, P. falciparum exacts the highest toll in …
[HTML][HTML] Mosquirix™ RTS, S/AS01 vaccine development, immunogenicity, and efficacy
Malaria is a parasitic infection caused by bites from Plasmodium falciparum (P. falciparum)-
infected mosquitoes with a present scale of symptoms ranging from moderate fever to …
infected mosquitoes with a present scale of symptoms ranging from moderate fever to …
Towards eradication of malaria: is the WHO's RTS, S/AS01 vaccination effective enough?
N Arora, LC Anbalagan, AK Pannu - Risk Management and …, 2021 - Taylor & Francis
Background Recent advances in mosquito eradication and antimalarial treatments have
reduced the malaria burden only modestly. An effective malaria vaccine remains a high …
reduced the malaria burden only modestly. An effective malaria vaccine remains a high …
[HTML][HTML] Malaria vaccines: progress to date
DI Stanisic, MF Good - BioDrugs, 2023 - Springer
Malaria is a mosquito-borne disease caused by protozoan parasites of the genus
Plasmodium. Despite significant declines in malaria-attributable morbidity and mortality over …
Plasmodium. Despite significant declines in malaria-attributable morbidity and mortality over …
[HTML][HTML] Malaria vaccines: the 60-year journey of hope and final success—lessons learned and future prospects
AA El-Moamly, MA El-Sweify - Tropical Medicine and Health, 2023 - Springer
Background The world has made great strides towards beating malaria, although about half
of the world population is still exposed to the risk of contracting malaria. Developing an …
of the world population is still exposed to the risk of contracting malaria. Developing an …
The RTS, S vaccine candidate for malaria
JA Regules, JF Cummings… - Expert review of …, 2011 - Taylor & Francis
Malaria continues to be a worldwide leading cause of morbidity and mortality, and the
development of an effective malaria vaccine remains a research imperative. Of the multiple …
development of an effective malaria vaccine remains a research imperative. Of the multiple …
[HTML][HTML] First results of phase 3 trial of RTS, S/AS01 malaria vaccine in African children
RTS, S Clinical Trials Partnership - New England Journal of …, 2011 - Mass Medical Soc
Background An ongoing phase 3 study of the efficacy, safety, and immunogenicity of
candidate malaria vaccine RTS, S/AS01 is being conducted in seven African countries …
candidate malaria vaccine RTS, S/AS01 is being conducted in seven African countries …
The RTS, S malaria vaccine
S Casares, TD Brumeanu, TL Richie - Vaccine, 2010 - Elsevier
RTS, S is the most advanced candidate vaccine against human malaria. During its
remarkable journey from conception and design in the early 1980s to the multicenter Phase …
remarkable journey from conception and design in the early 1980s to the multicenter Phase …
Long-term safety and efficacy of the RTS, S/AS02A malaria vaccine in Mozambican children
J Sacarlal, P Aide, JJ Aponte, M Renom… - Journal of Infectious …, 2009 - academic.oup.com
Background We previously reported that the RTS, S/AS02A vaccine had an acceptable
safety profile, was immunogenic, and demonstrated efficacy against Plasmodium falciparum …
safety profile, was immunogenic, and demonstrated efficacy against Plasmodium falciparum …
The RTS, S malaria vaccine: Current impact and foundation for the future
JG Beeson, L Kurtovic, C Valim, KP Asante… - Science Translational …, 2022 - science.org
The RTS, S vaccine has recently been recommended for implementation as a childhood
vaccine in regions with moderate-to-high malaria transmission. We discuss mechanisms of …
vaccine in regions with moderate-to-high malaria transmission. We discuss mechanisms of …